Xlife Sciences AG (XLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xlife Sciences AG (XLS) has a cash flow conversion efficiency ratio of -0.003x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-803.62K ≈ $-1.02 Million USD) by net assets (CHF303.42 Million ≈ $383.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xlife Sciences AG balance sheet quality to measure how much of total assets are equity-financed.
Xlife Sciences AG - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xlife Sciences AG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Xlife Sciences AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xlife Sciences AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
-0.145x |
|
Quartzsea Acquisition Corporati
NASDAQ:QSEA
|
0.000x |
|
CSU Digital S.A.
SA:CSUD3
|
-0.626x |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
0.013x |
|
QES Group Bhd
KLSE:0196
|
0.036x |
|
Wallbridge Mining Company Limited
TO:WM
|
-0.007x |
|
Hannong Chem
KO:011500
|
0.058x |
|
Unic Technology
TWO:5452
|
0.064x |
Annual Cash Flow Conversion Efficiency for Xlife Sciences AG (2019–2024)
The table below shows the annual cash flow conversion efficiency of Xlife Sciences AG from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see XLS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF305.26 Million ≈ $385.93 Million |
CHF-421.51K ≈ $-532.90K |
-0.001x | -315.57% |
| 2023-12-31 | CHF268.17 Million ≈ $339.04 Million |
CHF171.78K ≈ $217.18K |
0.001x | +103.27% |
| 2022-12-31 | CHF235.23 Million ≈ $297.40 Million |
CHF-4.61 Million ≈ $-5.83 Million |
-0.020x | +4.32% |
| 2021-12-31 | CHF211.23 Million ≈ $267.06 Million |
CHF-4.32 Million ≈ $-5.47 Million |
-0.020x | -563.59% |
| 2020-12-31 | CHF130.17 Million ≈ $164.57 Million |
CHF-401.55K ≈ $-507.67K |
-0.003x | +24.57% |
| 2019-12-31 | CHF97.38 Million ≈ $123.11 Million |
CHF-398.24K ≈ $-503.48K |
-0.004x | -- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more